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Abstract:

New biomarkers with improved accuracy could be helpful for monitoring disease in
patients with Non-Hodgkin’s lymphomas (NHL). Towards this end, we have explored
the feasibility of identifying the sequence of rearranged IgH genes using nextgeneration sequencing, then using PCR to detect specific rearranged DNA fragments
in patients’ plasma. By capturing and sequencing the IgH genomic regions (IgCap),
we were able to detect and precisely determine the sequence of rearranged IgH loci
in the tumors of three NHL patients. Moreover, circulating rearranged DNA fragments
could be identified in the plasma of all three patients. Even in cases wherein tumor
biopsies were unavailable, we were able to use the IgH capture approach to identify
rearranged DNA loci in the plasma of 8 of 14 patients. IgCap may enable a more informed
management of selected patients with NHL and other B-cell malignancies in the future.

Introduction

to conventional disease indicators.[6] In liquid tumors
such as leukemias, consistently fused genes like BCRABL provide extraordinarily useful markers for following
patients during their treatment.[7] In leukemia patients,
rearrangements can be accessed in the blood or bone
marrow by virtue of the fact that any residual cancer
cells will reside in these compartments.[8] In tumors
such as lymphomas, however, circulating cells are not
consistently found in patients’ blood or marrow. Based
on the above-cited results on solid tumors, however, we
hypothesized that somatically rearranged DNA templates
from lymphomas might be found in the cell-free fraction
of blood, i.e., the plasma.
To test this hypothesis, and to develop a generally
applicable tool for companion diagnostics of B-cell
lymphomas, it was first necessary to identify aberrant
DNA sequences that could be identified in lymphoma
patients. Though no specific point mutations or
oncogene rearrangements are found in lymphomas in
general, virtually all lymphomas harbor rearrangements
in their immunoglobulin (Ig) genes.[9] Clever assays

As cancer chemotherapeutics improve, the need
for companion diagnostics to monitor the effects of such
therapeutics becomes progressively more important.
[1] The ideal marker would be one that can be simply
assessed without the need for repeat biopsies or exposure
to irradiation, is absolutely specific for the presence of
the tumor (to avoid false positives), is sensitive for the
presence of disease, and is cost-effective.[2] Among the
many new biomarkers being developed, those employing
free, circulating somatically mutated DNA sequences
in the plasma are particularly attractive because they
can in theory meet all these criteria.[3, 4] In particular,
mutations are exquisitely tumor-specific because they are
not found in any collection of normal cells in the patient,
and thereby have advantages over markers that are simply
associated with tumors, such as CEA or PSA.[5]
Circulating mutant DNA has been found in a variety
of solid tumors and initial studies have shown them to
provide sensitivity and specificity comparable or superior
www.impactjournals.com/oncotarget
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Results

that reveal such rearrangements have been described,
particularly those employing multiplex PCR to identify
clonal rearrangements upon electrophoresis through an
increase in the signal of a fragment “spike” representing
the rearrangement.[10] Though such assays are clinically
useful in many situations, the “spikes” representing clonal
rearrangements can be difficult to detect, either because
of inefficient primer annealing to the hypermutated
sequences in rearranged Ig genes. More importantly, such
assays cannot provide optimal sensitivity, as the tumorspecific spikes are overlaid on a background of normal
Ig rearrangements. The tumor-specific rearrangements
can therefore only be observed if their abundance
is significantly greater than the aggregate level of
rearrangements from normal B cells. Nonetheless, the
appearance of such spikes in plasma correlates with
the presence of lymphoma and persistence of such
spikes following chemotherapy seems to portend a poor
prognosis. To enhance the specificity of this plasma-based
approach, we set out to use a capture-and-sequence method
to more specifically identify rearrangements of IgH genes
at the sequence level then to use this information to detect
the same rearrangements in the plasma of NHL patients.

Strategy
We chose to identify the rearrangements in DNA
rather than RNA because RNA of adequate quality is
not available in many clinical situations while DNA can
be readily obtained even from archival samples. IgCap
involves three steps: (i) the tumor DNA is first randomly
sheared and ligated to adapters that allow their subsequent
amplification by PCR; (ii) fragments containing IgH genes
are captured on a solid support containing the sequences
of interest [11]; and (iii) the captured DNA is amplified
by conventional PCR, producing an IgCap library, and
the ends of the captured DNA fragments are subjected to
massively parallel sequencing.
The sequence information obtained is then processed
in silico to identify rearranged sequences. Note that IgCap
captures all fragments containing relevant IgH gene
sequences, not simply the rearranged fragments. Moreover,
the actual targets of this analysis, i.e., the rearranged loci,
are nearly always mutated, both within the exons and at

Table 1: Sequencing summary
Patient ID

Total tags

Bases
Sequenced

Target
Tags
Tags
Average Target bases
Tags
bases
Bases
Bases
matched to
matched
with
matched
coverage with more
uniquely to matched to
the Ig
matched to
to the Ig
of the Ig than 10 reads
more
genome
the Ig region
human
coding
(number)
region
region
than 10
sequences
genome
reads (%)

Patient 1

18,889,095

944,454,750

7,359,299

367,964,950 214,548

88,916

10,727,400

251

14437

61%

Patient 2

3,183,730

159,186,500

1,109,460

55,473,000

166,626

97,334

8,331,300

275

13826

59%

Patient 3

11,265,224

563,261,200

6,077,027

303,851,350 164,494

78,858

8,224,700

223

14373

61%

Patient 4

17,306,516

865,325,800

5,053,458

252,672,900 320,330

162,534

16,016,500

459

14401

61%

Patient 5

11,149,375

557,468,750

4,385,951

219,297,550 114,142

52,816

5,707,100

149

13912

59%

Patient 6

4,166,839

208,341,950

2,351,275

117,563,750 119,952

59,362

5,997,600

168

14588

62%

Patient 7

3,875,106

193,755,300

2,405,508

120,275,400 125,808

64,365

6,290,400

182

14611

62%

Patient 8

9,741,614

487,080,700

6,221,945

311,097,250 131,132

57,886

6,556,600

163

14726

62%

Patient 9

2,673,399

133,669,950

1,391,649

69,582,450

19,443

1,814,200

55

13541

57%

Patient 10

16,909,387

845,469,350

10,206,055 510,302,750 156,254

70,047

7,812,700

198

14656

62%

Patient 11

15,218,254

760,912,700

7,460,806

373,040,300 450,949

268,217

22,547,450

757

15888

67%

Patient 12

9,693,373

484,668,650

5,592,951

279,647,550 145,140

64,939

7,257,000

183

14526

62%

Patient 13

3,344,057

167,202,850

1,982,627

99,131,350

53,919

31,062

2,695,950

88

13644

58%

Patient 14

16,818,309

840,915,450

6,464,306

323,215,300 334,392

155,854

16,719,600

440

14642

62%

Patient 15

22,785,641 1,139,282,050 12,265,838 613,291,900 830,469

609,774

41,523,450

1721

16851

95%

Patient 16

19,547,977

11,370,485 568,524,250 789,493

586,682

39,474,650

1656

16866

95%

Patient 17

21,925,769 1,096,288,450 12,059,079 602,953,950 701,194

503,556

35,059,700

1421

16837

95%

977,398,850
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Identification of rearranged IgH genes directly
from plasma

the borders of the rearranged exons. Both these features
make the identification of rearrangements challenging,
particularly when only a relatively small number of bases
from each fragment are determined, as with the Illumina
instrument. However, we were able to develop algorithms
that could identify rearranged IgH genes on the basis of
several features that distinguish them from unrearranged
genes. In brief, we developed two algorithms, one that
could be used for analysis of one end of a tag and the
other for both ends in paired-end reads. The first algorithm
(called the “CTGGGG-algorithm) identified “seed”
fragments that contained a 6 nt sequence which was
identical to, or differed at one position, from a conserved
sequence present in all J genes (CTGGGG). The second
algorithm (called the “paired-end algorithm”), used
paired-end reads to identify two sets of seed fragments.
The first set included fragments related to normal V, D or
J regions but whose ends represented sequences separated
by >10000 bp in unrearranged DNA and in the expected
orientation. The second set included fragments in which
one of the two ends was related to normal V regions and
the other end included specific sequences within J or D
regions. The J-specific sequence was CTGGGCCA,
while the D-specific sequences included the middle five
bases of each of the D regions. In both algorithms, seed
fragments were extended to include larger regions of V,
D or J by performing homology searches among the other
fragments in the sequenced IgCap library.
To determine the sensitivity of these algorithms
for identifying rearranged IgH genes, we tested it on 89
known rearrangements recorded in the IMGT/LIGM-DB
database (Supplementary Table 1). We randomly cleaved
~100,00 bases spanning each rearrangement in silico to
generate a virtual library of overlapping fragments of
100 bp that mimicked the size of the DNA fragments
actually used to make IgCap libraries. Each library was
then analyzed using the two algorithms. The combination
of the alogorithms resulted in the identification of all 89
re-arrangements. No rearrangements were detected in
analogous in silico libraries constructed from unrearranged
IgH loci.

Patient 1
MW

Plasma

Con

Patient 2
Plasma

Con

Using the approach described above, we first
attempted to directly identify IgH gene rearrangements
in DNA purified from plasma in 14 patients in whom no
tumor tissue was available (clinical characteristics are
described in Supplementary Table 2). We used an Illumina
GA2 sequencer to analyze one end of each tag, employing
one lane per patient. We were thereby able to generate
2,673,399 to 18,889,095 tags of high quality from the
14 patients (Table 1). In ten of the samples, we identified
putative rearrangements (Table 2). We applied the same
procedure to the plasma DNA of two individuals without
B-cell neoplasia, and did not identify any rearrangements.
We then designed primer pairs (Supplementary Table 3)
that straddled the ten NHL patient rearrangements and used
them to PCR-amplify DNA from the same plasma samples.
In eight of the ten cases, we identified PCR products of
the expected size in the plasma of the appropriate patients
but not in DNA from normal individuals (Figure 1). The
PCR fragments were excised from the gel, cloned, and
sequenced. In each case, the sequence was that predicted
from the algorithm (with the exception of a single base
substitution that could have arisen during cloning, whole
genome amplification or clonal progression).

Identification of rearranged IgH genes in tumors
Though the results described above were encouraging,
we could not definitively identify rearrangements in 6 of
the 14 patients. Moreover, the number of IgCap library
fragments containing sequences corresponding to the
rearranged gene was generally small, ranging from 1
to 11 in those patients in which a rearrangement could
be identified. Plasma DNA is certainly not enriched in
rearranged fragments, and most IgH gene-containing DNA
fragments from plasma are undoubtedly derived from
non-tumor tissue. To improve the sensitivity of IgCap,
two modifications were made. First and most importantly,
we used a portion of the original lymphoma, rather than

Patient 3 Patient 4 Patient 5 Patient 6
Plasma

Con

Plasma

Con

Plasma

Con

Plasma

Con

Patient 7 Patient 8
Plasma

Con

Plasma

Con

125 bp
100 bp

75 bp

Figure 1: PCR amplification of Ig rearrangements in plasma. DNA was purified from either the plasma of patients or from normal
cells of an unrelated patient (Con). MW, molecular weight markers, size indicated on left in base pairs (bp).
www.impactjournals.com/oncotarget
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the plasma, to identify rearrangements, then used plasma
to determine whether the rearranged IgH gene could be
detected in the circulation. Second, it became possible
to sequence both ends of library fragments (“paired-end
reads”) during the course of this study, and this sequencing
approach was employed in the remaining experiments.
This modified strategy was applied to DNA isolated
from the involved lymph nodes of three NHL patients
(clinical information in Supplementary Table 2). From a
single lane of an Illumina GAIIx sequencer, we recovered
20 million tags of high sequence quality, 6-7% of which
contained homology to V, D, or J regions (Table 1). In each
of the three patients, IgCap identified two rearrangements
that were represented by more than 8 tags (Table 2). One
of the two rearrangements in each patient was presumably
derived from the maternal allele and the other from
the paternal allele. Importantly, the number of IgCap
library fragments containing sequences that bridged the
rearrangement was more than one in each case, ranging
from 8 to 36. In two of the six rearrangements, we could
identify both VD and DJ junctions. In the remaining 4, we
could only identify the DJ junction. We did not determine
whether this was due to technical vs. biologic reasons; it
is well-known that incomplete rearrangements, in which
D is fused to J but V is not fused to D, occur in neoplastic
B-cells.[12]
PCR primers that straddled the six rearrangements
were used to amplify DNA from the three tumors. In each
case, PCR products of the expected size were found in
the tumors of the appropriate patients but not in germline DNA from normal individuals (Figure 2). The
PCR fragments were excised from the gel, cloned, and
sequenced. In each case, the sequence was that predicted
from the IgCap data.
We next attempted to determine whether the
rearranged fragments could be identified in the plasma of
these three patients. In all cases, both rearranged fragments
were evident and could be detected in as little as 30 ul
of plasma (Figure 2). The PCR fragments from plasma
were cloned and found to be identical in sequence to
those of the corresponding patients’ tumors. The number
of rearranged fragments was determined by digital PCR

Patient 15
MW

Con

Plasma Tumor

Con

Plasma

and found to vary from 30 to 100 fragments per ml of
plasma. These rearrangements were not detected in DNA
from circulating cells from the same patients, even when
the DNA from as many as 1 million circulating cells were
assessed. . These results are consistent with the idea that
lymphoma cells are rare in the circulation and that the
rearranged DNA is released from the tumors in situ rather
than derived from circulating lymphoma cells.

Discussion
The results described above show that rearranged
IgH genes can be routinely identified in NHL tumors,
that the rearranged genes are present in the circulation at
detectable levels, and that the circulating DNA is more
abundant than circulating lymphoma cells. Moreover,
the IgCap approach is powerful enough to identify some
patients’ rearrangements directly from plasma if no tumor
biopsy is available. These results set the stage for clinical
implementation of this type of biomarker to follow the
course of NHL patients following therapy.
The clonal assessment of rearrangements in
immunoglobulin or T cell receptor genes has a long history.
[10] Initially, Southern blotting was the gold standard for
this type of analysis, but required large amounts of high
quality genomic DNA and lacked the sensitivity required
for many types of diagnostic assays. Southern blotting
was replaced with PCR-based assays, which have many
advantages. Primer sets facilitating multiplex PCR assays
have been painstakingly designed and shown to detect
up to 74% DLBCL and 96% FL.[13] Massively parallel
sequencing of PCR products derived from such primer sets
has recently been used to identify VDJ rearrangements in
Ig or T-cell receptor genes. [14-16] The massively parallel
sequencing approach used herein, in which VDJ genes are
captured rather than amplified using Ig-specific primers,
represents another means towards the identification
of clonal rearrangements and their use as biomarkers.
Though more complex than the direct PCR approach, it
has the advantage of being less biased; in theory, it should
detect 100% of rearranged fragments from lymphomatous
tissues. Additionally, it can be applied to degraded DNA

Patient 16
Tumor

Con

Plasma Tumor

Con

Patient 17
Plasma Tumor

Con

Plasma Tumor

Con

Plasma Tumor

125 bp
100 bp
75 bp

Figure 2: PCR amplification of Ig rearrangements in tumors and plasma. Two Ig rearrangements are shown for each patient

sample. DNA was purified from either from the tumor and plasma of patients or from normal cells of an unrelated patient (Con). MW,
molecular weight markers, size indicated on left in base pairs (bp).
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Table 2: Rearrangements identified in this study
Patient ID

Sample type

Patient 1

Plasma

Patient 2

Plasma

Patient 3

Plasma

Patient 4

Plasma

Patient 5

Plasma

Patient 6

Plasma

Patient 7

Plasma

Patient 8

Plasma

Patient 9

Plasma

Patient 10

Plasma

Patient 11
Patient 12
Patient 13
Patient 14

Plasma
Plasma
Plasma
Plasma

Patient 15

Primary tumor

Patient 15

Primary tumor

Patient 16

Primary tumor

Patient 16*

Primary tumor

Patient 17

Primary tumor

Patient 17

Primary tumor

Rearranged Sequence Identified
CTGGGTGGATTCTGAACAGCCCCGAGTCACGGTGGGTATAGTGGGAG
CCGAGGCCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGT
GAGTCCT
GCAGACACGGCTGTGTATTACTGTGCGAGACTGGGATCCCCGTATAGC
AGCAGCTGGCCCTACTACTACGGTATGGACGTCTGGGGCCAAGGGAC
CACGGTCACCGTCTC
CCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGAGTGTTGATTATT
CTGGGGACACCTTCCATAACCCATCCCTCAAGAGTCGCGTCTCCATATT
AATAGACGCGTCTAAAAACGTTTTCTCTCTGAGGTTGACTTTTGTTACC
GCCGCGGACACGGCCATATATTATTGTGCGGGACATCCTCATAGTACT
GGGTGGTATCAATCTGGGAACTGGTTCGACTCCTGGGGCCAGGGAAC
CCCGGTCACCGTCTCCTCA
CCGCGGACACGGCCATCTATTACTGTGCGAGAGATAAAGCAGATAAA
ACATTACGATGGCCCAAGACCTTAAACTGGTTCGACCCCTGGGGCCAC
GGAACCCTGGTCACC
CCTGTGGACACAGCCACATATTACTGTGCAGCAGTAGAACTAATTGAG
GCCGGCATGGAACTTGGCTACTGGGGCCCCCGGGAATCCTGGTCAAC
GTCTCCTCAGGTGAGTCCTC
TGTCACTGTGGTATTACGATTCTTTGACTGGTTGTTGTCAGCGCGACCC
CTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGT
GA
CCAGGTGTGGTTATTGTCAGGGGGTGCCAGGCCGTGGTAGAGATGGC
TACAACTACCAACCACGAGGGTACTACTTTGACTACTGGGGCCAGGGA
ACCCTGGTCACC
CAGGCCGTGGTAGAGATGGCTACAATCAGGATTGCATGGTCGTCGTTT
ACGGGGGGTTTTCTACTGGGGCCAGGGAACCCTGGTCACCGTCTC
TGTGGTATTACTATGATAGTAGTGTGAGGGGCCAGGGAACCCTGGTC
ACCGTCTCCTCA
AACCGAGGACACAGCCGTGTATTACTGTACCACAGGGGCGTACTGGG
GCCAGGGAACCCT
TCTGTGACCGCCGCAGACACGGCTGTGTATTTTTGTGCGAGGCAGGTT
GCGACGCAGGGGGCCCCCTTTGACTTCTGGGGCCGGGGAACCCTGAT
CACCGTCTCCTCAGGTGAGTCCT
TGAGGTCTGTGTCACTGTGATATTATGATACTTTGACTGGTTATTTGAG
AAAGTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGG
GTACGTGCCATGTTAGGATTTTGATCGAGGAGACAGCACCATGGGTAT
GGTTTCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGGTGA
TTCCAGGTGTGGTTATTGTCAGGCGATGTCAGACTGTGGTGGATATAG
TGGCTACGATCCCTCACCTTCTGGGGCCAAGGGACAATGGTCACCGTC
TCTTCAGGTAAGATGGCT
GTAGGGACAGGAGGATTTTGTGGGGGCTCGAGTCACTGTGAGCATAT
TGTGGTGGTGATTGCTCCGCTGAATACTTCCACCACTGGGGCCAGGGC
ACCCTGGTCACCGTCTCC
TCTTCAAATGAACAACCTGAGAGTCGAGGACACGGCCGTTTATTACTG
TACGAGAGAGACAAATTGTGACTACTGGGGCCAGGGAACCCTGGTCA
CCGTCTCCTCAGGTGA

Rearranged
Genes

Validated by PCR*

IGHD1-1:J5

Yes

IGHV4-30-2:J6

Yes

IGHV4-4:J5

Yes

IGHD4-23:J5

Yes

IGHV2-5:J5

Yes

IGHD3-9:J4

Yes

IGHD5-24:J4

Yes

IGHD5-24:J4

Yes

IGHD3-22:J5

No

IGHV3-49:J4

No

-

No
No
No
No

IGHV4-30-2:J4

Yes

IGHD3-9:J4

Yes

IGHD3-10:J1

Yes

IGHD5-12:J3

Yes

IGHD2-21:J1

Yes

IGHV3-53:J5

Yes

* The sequence identified through analysis of the IgCap libraries was identical to that determined from analysis of the PCR
products used for validation except in Patient 16, in which the sequence differed by a single base (G > A) at position 25.

www.impactjournals.com/oncotarget

182

Oncotarget 2011; 2: 178 - 185

samples such as those from paraffin-embedded material
or plasma. Degraded DNA cannot efficiently be amplified
with conventionally used primer sets because the product
size is larger than the size of the DNA.
We used two algorithms to identify rearranged
Igs. The CTGGGG-based algorithm detects all typical
rearranged Igs. However, this algorithm can fail to detect
uncommon Ig rearrangements such as those involving
only V and D or those involving J region deletions. The
paired-end algorithm is complementary. It has the capacity
to pick out any rearrangement involving the IgH locus,
including Ig rearrangements as well as translocations such
as t(8;14)(q24;q32) in Burkitt lymphoma and t(11;14)
(q13;q32) in mantle cell lymphoma.
As with all biomarkers, the approach described here
has limitations. Its major conceptual limitation revolves
around marker stability: a relapsed lymphoma may have
undergone clonal divergence so that its rearrangement
would be undetectable upon PCR with the primers
used to validate the original tumor.[17] It was therefore
comforting that in each of the three NHL tumor samples
evaluated in this study, two distinct rearrangements were
identified, and both could be identified in the plasma of
each patient. The availability of two independent markers
reduces the probability of a false negative during followup. Because the exact sequence of the rearrangement is
determined with our approach, two sets of primers for
each rearrangement could be employed, thereby further
minimizing the potential impact of clonal evolution within
the rearranged loci.
Enthusiasm has been growing for risk-adapted
therapy in the treatment of diffuse large B cell lymphoma.
Mid cycle FDG PET has been used to guide decisions on
switching chemotherapy regimens and to select patients for
high dose consolidation.[18],[19] However, standardized
interpretation of PET imaging still presents obstacles, as
recently noted in an ongoing cooperative group trial.[20]
The plasma-based approach described here represents an
alternative and perhaps complementary approach to tumor
assessment. Another important issue to be addressed in
the future is the sensitivity of the method. In this work,
we have only evaluated patients with clinically apparent
disease. It may be more difficult to detect rearranged IgH
genes in the plasma of patients with minimal residual
disease following therapy. However, we were encouraged
by the fact that rearrangements can be detected in as little
as 30 ul of plasma in the three patients whose levels were
quantified. This suggests that disease burdens amounting
to only 1% of those of the studied patients could be readily
detected in 3 ml of plasma, assuming the relationship
between disease burden and plasma DNA is linear.
Do the rearrangements detected with IgCap
represent those occurring in the tumor cells? In the
three cases in which the rearrangements were identified
in the tumor, there can be little doubt of this, as the
number of IgCap library fragments corresponding to the
www.impactjournals.com/oncotarget

major rearrangement outnumbered any other putative
rearrangements in the sample by more than a hundred-fold.
In the cases in which only plasma DNA was available, it
is theoretically possible that the identified rearrangements
arose from normal B-cells. Two observations argue
against this possibility. First, we have attempted the IgCap
strategy on two samples of plasma from patients without
B-cell neoplasms and have not identified any rearranged
fragments in IgCap libraries from them. Second, there
were two patients in whom a plasma sample taken during
complete remission was available, and the rearrangements
could not be identified in these either (through PCR with
the rearrangement-specific primers). Regardless, it is
clearly optimal to identify the rearranged biomarker by
employing the IgCap strategy on DNA from lymphomas,
rather than from plasma, whenever the former is available.
The biomarker can then be easily applied to plasma using
PCR, as described above.
In sum, IgCap is an advanced, personalized medicine
approach that provides exciting research opportunities
and offers the potential for clinical application. The
basic idea of IgCap could be applied to other diseases,
including those with an autoimmune or allergic basis,
to define the number and nature of Ig rearrangements in
clinical samples. With minor modifications, it might also
be applied to the evaluation of T-cells.

Materials and Methods
Samples
All samples in this study were obtained from patients
under an Institutional Review Board protocol.

DNA purification
DNA was extracted from 1000 µL of plasma with
a QIAamp Circulating Nucleic Acid kit following the
manufacturer’s instructions. (QIAGEN; Valencia, CA).
DNA was extracted from tumor tissues and normal cells
using a Qiagen AllPrep kit following the manufacturer’s
protocol.

Illumina library preparation
Tumor genomic DNA libraries were prepared
following Illumina’s (Illumina, San Diego, CA) protocol
with the following modifications. (1) Three micrograms
(µg) of genomic DNA in 100 microliter (µl) of TE was
fragmented in a Covaris sonicator (Covaris, Woburn,
MA) to a size of 100-500bp. DNA was purified with a
PCR purification kit (Cat # 28104, Qiagen, Valencia,
CA) and eluted in 35µl of elution buffer included in the
183
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Confirmation of IgH rearrangements in tumor
and plasma samples

kit. (2) Purified, fragmented DNA was mixed with 40 µl
of H2O, 10 µl of 10xT4 ligase buffer with 10mM ATP,
4 µl of 10mM dNTP, 5 µl of T4 DNA polymerase, 1 µl
of Klenow Polymerase, and 5 µl of T4 polynucleotide
Kinase. All reagents used for this step and those described
below were from New England Biolabs (NEB, Ipswich,
MA) unless otherwise specified. The 100µl end-repair
mixture was incubated at 20oC for 30 min, purified by
a PCR purification kit (Cat # 28104, Qiagen) and eluted
with 32µl of elution buffer (EB). (3) To A-tail, all 32 µl
of end-repaired DNA was mixed with 5 µl of 10xBuffer
(NEB buffer 2), 10 µl of 1mM dATP and 3 µl of Klenow
(exo-). The 50 µl mixture was incubated at 37oC for 30
min before DNA was purified with a MinElute PCR
purification kit (Cat # 28004, Qiagen). Purified DNA was
eluted with 12.5 µl of 70oC EB. (4) For adaptor ligation,
10 µl of A-tailed DNA was mixed with 10 µl of adapters
(Illumina), 25 µl of 2x Rapid Lgase buffer and 5 µl of
Rapid Ligase. The ligation mixture was incubated at room
temperature (RT) for 15 min. (5) To purify adapter- ligated
DNA, 50 µl of ligation mixture from step (4) was mixed
with 200 µl of NT buffer from NucleoSpin Extract II kit
(cat# 636972, Clontech, Mountain View, CA) and loaded
into a NucleoSpin column. The column was centrifuged at
13,000 g in a desktop centrifuge for 1 min, washed once
with 600 µl of wash buffer (NT3 from Clontech), and
centrifuged again for 2 min to dry completely. DNA was
eluted in 50µl elution buffer included in the kit. (6) To
obtain an amplified library, ten PCRs of 25 µl each were
set up, each including 12 µl of H2O, 5 µl of 5 x Phusion
HF buffer, 0.5 µl of 10 mM dNTP, 1.25 µl of DMSO, 0.5
µl of Illumina PE primer #1, 0.5 µl of Illumina PE primer
#2, 0.25 µl of Hotstart Phusion polymerase, and 5 µl of
the DNA from step (5). The PCR program used was: 98oC
1 minute; 6 cycles of 98oC for 20 seconds, 65oC for 30
seconds, 72oC for 30 seconds; and 72oC for 5 min. To
purify the PCR product, 250 µl PCR mixture (from the
ten PCR reactions) was mixed with 500 µl NT buffer from
NucleoSpin Extract II kit and purified as described in
step (5). Library DNA was eluted with elution buffer preheated to 70oC and the DNA concentration was estimated
by absorption at 260 nm.

The full V-D-J or D-J joint region sequence and
40 bp from either side of the joint were used for primer
design. The PCR mixture (50 μl) contained various
amounts of template DNA, 0.2 μM of forward-reverse
primer mixture, 2.5 mM of MgCl2, 100 μM of dNTPs,
and 0.5 units of Invitrogen Taq polymerase. PCR was
performed as follows: 96°C for 4 min; 45 cycles of 96°C
for 10 s, 59°C for 10 s , and 72°C for 30 s. The primers
used for PCR are listed in Supplementary table 3. PCR
products were gel purified with QIAquick Gel Extraction
Kit (QIAGEN; Valencia, CA) and cloned with a TA
clone kit (Promega, Madison, WI, USA) according to the
manufacture’s protocols. Plasmid DNA was evaluated
by Sanger sequencing. Digital PCR was performed as
described before.[22]
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